BridgeBio Oncology Therapeutics, Inc.
BBOT Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$2.66
6.7%What BridgeBio Oncology Therapeutics, Inc. does
No business description yet.
- Legal name
- BridgeBio Oncology Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Accession · CIK
- 0001193125-26-094112
0001869105
Revenue and margins
BridgeBio Oncology Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$115M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
BridgeBio Oncology Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 241,332.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably BridgeBio Oncology Therapeutics, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.3M | $156M | $425M |
| Current ratio | — | 8.1x | 12.3x |
| Quick ratio | — | 8.1x | 12.3x |
| Total assets | $0.3M | $164M | $448M |
| Total liabilities | $0.4M | $19.6M | $37.3M |
| Shareholders' equity | −$116M | −$179M | $411M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | — | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ |
| Cash from operations exceeds net income | — | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | ✓ |
| Share count didn't rise | — | — | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 1 | — / 4 | — / 6 |
| Accruals ratio | — | −23.4% | −6.6% |
| Altman Z'' | — | −11.75 | 12.61 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | — | $73.1M | $121M |
| Operating income | −$0.0M | −$80.9M | −$146M |
| Income tax | — | $0.0M | $0.0M |
| Net income | −$0.0M | −$74.3M | −$134M |
| Diluted EPS | — | −$5,756.41 | −$4.30 |
| Diluted shares | — | 0.00B | 0.03B |
| Cash flow | |||
| Cash from operations | — | −$55.0M | −$114M |
| Capital expenditure | — | $0.0M | $0.6M |
| Free cash flow | — | −$55.1M | −$115M |
| Depreciation and amortization | — | $0.2M | $0.3M |
| Stock-based compensation | — | $4.4M | $5.9M |
| Balance sheet | |||
| Cash and short-term investments | $0.3M | $156M | $425M |
| Current assets | — | $159M | $432M |
| Current liabilities | $0.4M | $19.6M | $35.0M |
| Property and equipment, net | — | $0.5M | $1.0M |
| Total assets | $0.3M | $164M | $448M |
| Total liabilities | $0.4M | $19.6M | $37.3M |
| Shareholders' equity | −$116M | −$179M | $411M |
| Returns | |||
| Return on capital employed | 65.6% | −55.9% | −35.3% |
| Return on equity | — | — | −115.3% |
| Return on assets | −12.5% | −90.2% | −43.8% |
| Return on tangible equity | — | — | −32.6% |
| Growth | |||
| Share count change | — | — | 241,332.6% |
| Financial health | |||
| Current ratio | — | 8.1x | 12.3x |
| Quick ratio | — | 8.1x | 12.3x |
| Quality scores | |||
| Altman Z'' | — | −11.7 | 12.6 |
| Accruals ratio | — | −23.4% | −6.6% |
Source: SEC EDGAR XBRL filings (CIK 0001869105). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.